The Experts below are selected from a list of 312 Experts worldwide ranked by ideXlab platform
Verena Gafner - One of the best experts on this subject based on the ideXlab platform.
-
Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes.
Critical Care, 2014Co-Authors: Philippe Eggimann, Charles-edouard Luyt, Michel Wolff, Michael Tamm, Bruno François, Emmanuelle Mercier, Jorge Garbino, Pierre-françois Laterre, Holger Koch, Verena GafnerAbstract:INTRODUCTION: Pseudomonas aeruginosa frequently causes nosocomial pneumonia and is associated with poor outcome. The purpose of this study was to assess the prevalence and clinical outcome of nosocomial pneumonia caused by serotype specific Pseudomonas aeruginosa in critically ill patients under appropriate antimicrobial therapy management. METHODS: A retrospective, non-interventional epidemiological multicenter cohort study involving 143 patients with confirmed nosocomial pneumonia caused by Pseudomonas aeruginosa. Patients were analyzed for a period of 30 days from time of nosocomial pneumonia onset. Fourteen patients fulfilling the same criteria from a Phase IIa study conducted at the same time/centers were included in the prevalence calculations but not in the clinical outcome analysis. RESULTS: The prevalence of serotypes was: O6 (29%), O11 (23%), O10 (10%), O2 (9%) and O1 (8%). Serotypes with a prevalence < 5% were found in 13% of patients, 8% were classified as not typeable. Across all serotypes there was 19% mortality, 70% clinical resolution, 11% clinical continuation and 5% clinical recurrence. Age and higher APACHE II were predictive risk factors associated with probability of death and lower clinical resolution for Pseudomonas aeruginosa nosocomial pneumonia. Mortality tends to be higher with O1 (40%) and lower with O2 (0%); clinical resolution tends to be better with O2 (82%) compared to other serotypes. Persisting pneumonia with O6 and O11 was respectively 8% and 21%; clinical resolution with O6 and O11 was respectively 75% and 57%. CONCLUSIONS: In Pseudomonas aeruginosa nosocomial pneumonia, the most prevalent serotypes were O6 and O11. Further studies including larger group sizes are needed to correlate clinical outcome with virulence factors of Pseudomonas aeruginosa in patients with nosocomial pneumonia caused by various serotypes; and to compare O6 and O11, the 2 serotypes most frequently encountered in critically ill patients.
Philippe Eggimann - One of the best experts on this subject based on the ideXlab platform.
-
Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes.
Critical Care, 2014Co-Authors: Philippe Eggimann, Charles-edouard Luyt, Michel Wolff, Michael Tamm, Bruno François, Emmanuelle Mercier, Jorge Garbino, Pierre-françois Laterre, Holger Koch, Verena GafnerAbstract:INTRODUCTION: Pseudomonas aeruginosa frequently causes nosocomial pneumonia and is associated with poor outcome. The purpose of this study was to assess the prevalence and clinical outcome of nosocomial pneumonia caused by serotype specific Pseudomonas aeruginosa in critically ill patients under appropriate antimicrobial therapy management. METHODS: A retrospective, non-interventional epidemiological multicenter cohort study involving 143 patients with confirmed nosocomial pneumonia caused by Pseudomonas aeruginosa. Patients were analyzed for a period of 30 days from time of nosocomial pneumonia onset. Fourteen patients fulfilling the same criteria from a Phase IIa study conducted at the same time/centers were included in the prevalence calculations but not in the clinical outcome analysis. RESULTS: The prevalence of serotypes was: O6 (29%), O11 (23%), O10 (10%), O2 (9%) and O1 (8%). Serotypes with a prevalence < 5% were found in 13% of patients, 8% were classified as not typeable. Across all serotypes there was 19% mortality, 70% clinical resolution, 11% clinical continuation and 5% clinical recurrence. Age and higher APACHE II were predictive risk factors associated with probability of death and lower clinical resolution for Pseudomonas aeruginosa nosocomial pneumonia. Mortality tends to be higher with O1 (40%) and lower with O2 (0%); clinical resolution tends to be better with O2 (82%) compared to other serotypes. Persisting pneumonia with O6 and O11 was respectively 8% and 21%; clinical resolution with O6 and O11 was respectively 75% and 57%. CONCLUSIONS: In Pseudomonas aeruginosa nosocomial pneumonia, the most prevalent serotypes were O6 and O11. Further studies including larger group sizes are needed to correlate clinical outcome with virulence factors of Pseudomonas aeruginosa in patients with nosocomial pneumonia caused by various serotypes; and to compare O6 and O11, the 2 serotypes most frequently encountered in critically ill patients.
Zhu Xiao-ming - One of the best experts on this subject based on the ideXlab platform.
-
Observation on Pseudomonas aeruginosa biofilm with sliver staining method
Chinese Journal of Microecology, 2012Co-Authors: Zhu Xiao-mingAbstract:Objective To evaluate the effect of sliver staining method on the identification of Pseudomonas aeruginosa biofilms.Methods Sliver staining was carried out to identify the Pseudomonas aeruginosa biofilms which was constructed by plate method.Results Optical microscope and scanning electron microscope were used to observe the Pseudomonas aeruginosa biofilms after sliver staining.Conclusion Sliver staining method was simple and reliable for the identification of Pseudomonas aeruginosa biofilms.
-
In vitro Effect of MXSGD against Pseudomonas aeruginosa Biofilms
Lishizhen Medicine and Materia Medica Research, 2012Co-Authors: Zhu Xiao-mingAbstract:Objective To investigate the effect of Maxing Shigan Decoction(MXSGD) against Pseudomonas aeruginosa biofilms in vitro.Methods Microdilution method was used to detect minimal inhibitory concentrations(MIC) of MXSGD and Azithromycin.Checkerboard method was used to examine the synersism of MXSGD combined Azithromycin.MTT assay was used to evaluate the effect of MXSGD on biofilms,and microscope was applied to observe biofilms morphology.Results SMIC50 and SMIC80 of MXSGD against Pseudomonas aeruginosa biofilms were 250 and 1000 mg·ml-1 respectively.MXSGD showed a significantly inhibitory effect on Pseudomonas aeruginosa biofilms morphology at 500mg·ml-1.Conclusion MXSGD can inhibit Pseudomonas aeruginosa biofilms in vitro.
Holger Koch - One of the best experts on this subject based on the ideXlab platform.
-
Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes.
Critical Care, 2014Co-Authors: Philippe Eggimann, Charles-edouard Luyt, Michel Wolff, Michael Tamm, Bruno François, Emmanuelle Mercier, Jorge Garbino, Pierre-françois Laterre, Holger Koch, Verena GafnerAbstract:INTRODUCTION: Pseudomonas aeruginosa frequently causes nosocomial pneumonia and is associated with poor outcome. The purpose of this study was to assess the prevalence and clinical outcome of nosocomial pneumonia caused by serotype specific Pseudomonas aeruginosa in critically ill patients under appropriate antimicrobial therapy management. METHODS: A retrospective, non-interventional epidemiological multicenter cohort study involving 143 patients with confirmed nosocomial pneumonia caused by Pseudomonas aeruginosa. Patients were analyzed for a period of 30 days from time of nosocomial pneumonia onset. Fourteen patients fulfilling the same criteria from a Phase IIa study conducted at the same time/centers were included in the prevalence calculations but not in the clinical outcome analysis. RESULTS: The prevalence of serotypes was: O6 (29%), O11 (23%), O10 (10%), O2 (9%) and O1 (8%). Serotypes with a prevalence < 5% were found in 13% of patients, 8% were classified as not typeable. Across all serotypes there was 19% mortality, 70% clinical resolution, 11% clinical continuation and 5% clinical recurrence. Age and higher APACHE II were predictive risk factors associated with probability of death and lower clinical resolution for Pseudomonas aeruginosa nosocomial pneumonia. Mortality tends to be higher with O1 (40%) and lower with O2 (0%); clinical resolution tends to be better with O2 (82%) compared to other serotypes. Persisting pneumonia with O6 and O11 was respectively 8% and 21%; clinical resolution with O6 and O11 was respectively 75% and 57%. CONCLUSIONS: In Pseudomonas aeruginosa nosocomial pneumonia, the most prevalent serotypes were O6 and O11. Further studies including larger group sizes are needed to correlate clinical outcome with virulence factors of Pseudomonas aeruginosa in patients with nosocomial pneumonia caused by various serotypes; and to compare O6 and O11, the 2 serotypes most frequently encountered in critically ill patients.
Pierre-françois Laterre - One of the best experts on this subject based on the ideXlab platform.
-
Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes.
Critical Care, 2014Co-Authors: Philippe Eggimann, Charles-edouard Luyt, Michel Wolff, Michael Tamm, Bruno François, Emmanuelle Mercier, Jorge Garbino, Pierre-françois Laterre, Holger Koch, Verena GafnerAbstract:INTRODUCTION: Pseudomonas aeruginosa frequently causes nosocomial pneumonia and is associated with poor outcome. The purpose of this study was to assess the prevalence and clinical outcome of nosocomial pneumonia caused by serotype specific Pseudomonas aeruginosa in critically ill patients under appropriate antimicrobial therapy management. METHODS: A retrospective, non-interventional epidemiological multicenter cohort study involving 143 patients with confirmed nosocomial pneumonia caused by Pseudomonas aeruginosa. Patients were analyzed for a period of 30 days from time of nosocomial pneumonia onset. Fourteen patients fulfilling the same criteria from a Phase IIa study conducted at the same time/centers were included in the prevalence calculations but not in the clinical outcome analysis. RESULTS: The prevalence of serotypes was: O6 (29%), O11 (23%), O10 (10%), O2 (9%) and O1 (8%). Serotypes with a prevalence < 5% were found in 13% of patients, 8% were classified as not typeable. Across all serotypes there was 19% mortality, 70% clinical resolution, 11% clinical continuation and 5% clinical recurrence. Age and higher APACHE II were predictive risk factors associated with probability of death and lower clinical resolution for Pseudomonas aeruginosa nosocomial pneumonia. Mortality tends to be higher with O1 (40%) and lower with O2 (0%); clinical resolution tends to be better with O2 (82%) compared to other serotypes. Persisting pneumonia with O6 and O11 was respectively 8% and 21%; clinical resolution with O6 and O11 was respectively 75% and 57%. CONCLUSIONS: In Pseudomonas aeruginosa nosocomial pneumonia, the most prevalent serotypes were O6 and O11. Further studies including larger group sizes are needed to correlate clinical outcome with virulence factors of Pseudomonas aeruginosa in patients with nosocomial pneumonia caused by various serotypes; and to compare O6 and O11, the 2 serotypes most frequently encountered in critically ill patients.
